Credit Suisse Group lowered shares of Pfizer, Inc. (NYSE:PFE) from an outperform rating to a neutral rating in a report released on Thursday morning. They currently have $36.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $38.00.
Several other equities research analysts have also recently weighed in on PFE. Jefferies Group LLC restated a hold rating and set a $35.00 target price (up from $34.00) on shares of Pfizer in a research note on Friday, July 14th. Cowen and Company set a $43.00 target price on Pfizer and gave the stock a buy rating in a research note on Monday, July 10th. Sanford C. Bernstein set a $39.00 target price on Pfizer and gave the stock a buy rating in a research note on Monday. BidaskClub cut Pfizer from a sell rating to a strong sell rating in a research note on Thursday, July 13th. Finally, Zacks Investment Research upgraded Pfizer from a sell rating to a hold rating in a research note on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and ten have issued a buy rating to the company. Pfizer currently has a consensus rating of Hold and a consensus price target of $37.68.
Shares of Pfizer (PFE) traded down 0.18% during trading on Thursday, reaching $33.48. The company’s stock had a trading volume of 12,024,304 shares. The firm’s 50-day moving average is $33.20 and its 200 day moving average is $33.25. The company has a market cap of $199.80 billion, a PE ratio of 28.18 and a beta of 1.01. Pfizer has a 52-week low of $29.83 and a 52-week high of $37.39. Pfizer also was the recipient of unusually large options trading on Tuesday. Stock traders acquired 21,983 put options on the stock. This represents an increase of 351% compared to the typical volume of 4,871 put options.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.02. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. The firm had revenue of $12.78 billion during the quarter, compared to analysts’ expectations of $13.09 billion. During the same period in the prior year, the company earned $0.67 earnings per share. The company’s quarterly revenue was down 1.7% on a year-over-year basis. On average, equities research analysts predict that Pfizer will post $2.55 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Pfizer, Inc. (NYSE:PFE) Downgraded to Neutral at Credit Suisse Group” was reported by BBNS and is the property of of BBNS. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/pfizer-inc-nysepfe-downgraded-to-neutral-at-credit-suisse-group/1248201.html.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a yield of 3.82%. Pfizer’s payout ratio is currently 108.48%.
A number of hedge funds have recently modified their holdings of the company. D Orazio & Associates Inc. increased its stake in shares of Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 28 shares during the last quarter. Northstar Group Inc. increased its stake in shares of Pfizer by 0.4% in the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 35 shares during the last quarter. Stone House Investment Management LLC increased its stake in shares of Pfizer by 0.9% in the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock worth $245,000 after buying an additional 66 shares during the last quarter. Naples Global Advisors LLC increased its stake in shares of Pfizer by 0.3% in the first quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock worth $840,000 after buying an additional 79 shares during the last quarter. Finally, Pure Financial Advisors Inc. increased its stake in shares of Pfizer by 0.4% in the first quarter. Pure Financial Advisors Inc. now owns 22,091 shares of the biopharmaceutical company’s stock worth $756,000 after buying an additional 84 shares during the last quarter. Hedge funds and other institutional investors own 69.95% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with our FREE daily email newsletter.